share_log

DekaBank Deutsche Girozentrale Purchases New Shares in Centogene (NASDAQ:CNTG)

Defense World ·  Jul 26, 2022 04:41

DekaBank Deutsche Girozentrale bought a new stake in shares of Centogene (NASDAQ:CNTG – Get Rating) in the 1st quarter, HoldingsChannel reports. The fund bought 16,319 shares of the company's stock, valued at approximately $67,000.

Separately, Acadian Asset Management LLC boosted its stake in Centogene by 16.2% in the 4th quarter. Acadian Asset Management LLC now owns 70,725 shares of the company's stock worth $366,000 after purchasing an additional 9,854 shares during the period.

Get Centogene alerts:

Analyst Ratings Changes

Separately, SVB Leerink lowered their price target on Centogene from $10.00 to $6.00 and set an "outperform" rating on the stock in a report on Monday, July 18th.

Centogene Trading Down 17.2 %

NASDAQ CNTG opened at $1.59 on Tuesday. The company has a quick ratio of 2.41, a current ratio of 2.48 and a debt-to-equity ratio of 0.67. Centogene has a twelve month low of $1.46 and a twelve month high of $11.75. The firm has a market capitalization of $31.58 million, a PE ratio of -0.66 and a beta of -0.95. The stock's 50 day moving average is $2.45 and its 200 day moving average is $3.44.

Centogene (NASDAQ:CNTG – Get Rating) last posted its quarterly earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. The business had revenue of $11.59 million during the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. Research analysts forecast that Centogene will post -1.72 earnings per share for the current fiscal year.

About Centogene

(Get Rating)

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.

Read More

  • Get a free copy of the StockNews.com research report on Centogene (CNTG)
  • Taking a Look at Nvidia's Stock Amidst The Semiconductor Chip Gut
  • Palantir Stock is Showing Signs of Life
  • The Institutions Like The Color Of PPG Industries
  • What Investors Need to Know to Beat the Market
  • Alcoa Is Well-Positioned For 2022 and 2023

Want to see what other hedge funds are holding CNTG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centogene (NASDAQ:CNTG – Get Rating).

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment